Altimmune Inc Cash Flow Conversion Efficiency
Altimmune Inc cash flow conversion efficiency. Based on the latest financial reports, Altimmune Inc (ALT) has a cash flow conversion efficiency ratio of -0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.45 Million) by net assets ($224.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Altimmune Inc (2005–2025)
Cash flow conversion efficiency of Altimmune Inc from 2005 to 2025. This chart illustrates how Altimmune Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Altimmune Inc stock quote for real-time trading data and today's change.
Altimmune Inc Cash Flow Conversion Ratio Explained
Altimmune Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Altimmune Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Altimmune Inc ranked by their cash flow conversion efficiency. Also see market value of Altimmune Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NICE Holdings Co. Ltd
KO:034310
|
0.070x |
|
Abrdn Emerging Markets Equity Income Fund Inc
NYSE MKT:AEF
|
-0.001x |
|
BTC Development Corp.
NASDAQ:BDCI
|
-0.001x |
|
Modern Avenue Group Co Ltd
SHE:002656
|
-0.393x |
|
ProCap Acquisition Corp Class A Ordinary Shares
NASDAQ:PCAP
|
-0.001x |
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
N/A |
|
Nanning Sugar Industry Co Ltd
SHE:000911
|
-10.540x |
|
Kabra Extrusion Technik Limited
NSE:KABRAEXTRU
|
-0.022x |
Annual Cash Flow Conversion Efficiency for Altimmune Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Altimmune Inc from 2005 to 2025. Review Altimmune Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $224.89 Million | $-67.53 Million | -0.300x | +53.55% |
| 2024-12-31 | $123.51 Million | $-79.85 Million | -0.647x | -65.53% |
| 2023-12-31 | $194.10 Million | $-75.81 Million | -0.391x | -15.63% |
| 2022-12-31 | $185.29 Million | $-62.59 Million | -0.338x | +14.03% |
| 2021-12-31 | $199.13 Million | $-78.24 Million | -0.393x | -157.70% |
| 2020-12-31 | $225.88 Million | $-34.44 Million | -0.152x | +27.72% |
| 2019-12-31 | $45.52 Million | $-9.60 Million | -0.211x | -8.54% |
| 2018-12-31 | $48.31 Million | $-9.39 Million | -0.194x | +53.20% |
| 2017-12-31 | $48.68 Million | $-20.21 Million | -0.415x | -104.01% |
| 2016-12-31 | $19.46 Million | $201.51 Million | 10.355x | +5461.03% |
| 2015-12-31 | $16.65 Million | $-3.22 Million | -0.193x | +58.34% |
| 2014-12-31 | $18.27 Million | $-8.47 Million | -0.464x | +52.54% |
| 2013-12-31 | $7.34 Million | $-7.17 Million | -0.977x | -391.08% |
| 2012-12-31 | $11.67 Million | $-2.32 Million | -0.199x | +59.61% |
| 2011-12-31 | $15.85 Million | $-7.81 Million | -0.493x | +59.53% |
| 2010-12-31 | $12.21 Million | $-14.86 Million | -1.217x | +91.85% |
| 2009-12-31 | $1.88 Million | $-28.15 Million | -14.936x | -2046.03% |
| 2008-12-31 | $18.96 Million | $-13.20 Million | -0.696x | -107.07% |
| 2007-12-31 | $40.57 Million | $-13.64 Million | -0.336x | -1355.97% |
| 2006-12-31 | $57.11 Million | $1.53 Million | 0.027x | +236.37% |
| 2005-12-31 | $69.68 Million | $554.33K | 0.008x | -- |
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.